<?xml version="1.0" encoding="UTF-8"?>
<p class="p">While Δ
 <sup class="sup">9</sup>-THC has led to the discovery of the endocannabinoid system, the molecular basis of CBD activity is still challenging pharmacologists, especially when conventional treatment is of no avail, e.g. for genetic epilepsy [
 <xref rid="B1-molecules-24-01138" ref-type="bibr" class="xref">1</xref>]. Many studies in the literature have proved that CBD has anxiolytic and neuroprotective properties [
 <xref rid="B13-molecules-24-01138" ref-type="bibr" class="xref">13</xref>,
 <xref rid="B14-molecules-24-01138" ref-type="bibr" class="xref">14</xref>,
 <xref rid="B15-molecules-24-01138" ref-type="bibr" class="xref">15</xref>] and, moreover, that it has anticholinesterase and antiemetic effects [
 <xref rid="B16-molecules-24-01138" ref-type="bibr" class="xref">16</xref>]. CBD and CBG have both revealed to exert antibacterial properties against a variety of methicillin-resistant 
 <italic class="italic">Staphylococcus aureus</italic> strains [
 <xref rid="B17-molecules-24-01138" ref-type="bibr" class="xref">17</xref>]. CBG has also shown anti-inflammatory activity [
 <xref rid="B18-molecules-24-01138" ref-type="bibr" class="xref">18</xref>], and it has been associated with muscle relaxation and analgesia by activating 
 <italic class="italic">α</italic>-2 receptors [
 <xref rid="B19-molecules-24-01138" ref-type="bibr" class="xref">19</xref>]. On the other hand, CBDA has been shown to possess an anti-proliferative effect on breast cancer cell migration [
 <xref rid="B20-molecules-24-01138" ref-type="bibr" class="xref">20</xref>].
</p>
